Titre : Mitomycine

Mitomycine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Unsupervised Machine Learning
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Mitomycine : Questions médicales les plus fréquentes", "headline": "Mitomycine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Mitomycine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-23", "dateModified": "2025-02-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Mitomycine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Mitomycines", "url": "https://questionsmedicales.fr/mesh/D008937", "about": { "@type": "MedicalCondition", "name": "Mitomycines", "code": { "@type": "MedicalCode", "code": "D008937", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.473.412.249" } } }, "about": { "@type": "MedicalCondition", "name": "Mitomycine", "alternateName": "Mitomycin", "code": { "@type": "MedicalCode", "code": "D016685", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Elise Champeil", "url": "https://questionsmedicales.fr/author/Elise%20Champeil", "affiliation": { "@type": "Organization", "name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA; The Graduate Center of the City University of New York, New York, NY 10016, USA. Electronic address: echampeil@jjay.cuny.edu." } }, { "@type": "Person", "name": "Owen Zacarias", "url": "https://questionsmedicales.fr/author/Owen%20Zacarias", "affiliation": { "@type": "Organization", "name": "Department of Sciences, John Jay College of Criminal Justice, New York, NY 10019, United States." } }, { "@type": "Person", "name": "Maggie Zheng", "url": "https://questionsmedicales.fr/author/Maggie%20Zheng", "affiliation": { "@type": "Organization", "name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: maggie.zheng@jjay.cuny.edu." } }, { "@type": "Person", "name": "Timothy Snyder", "url": "https://questionsmedicales.fr/author/Timothy%20Snyder", "affiliation": { "@type": "Organization", "name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: timothy.snyder@jjay.cuny.edu." } }, { "@type": "Person", "name": "Gloria Proni", "url": "https://questionsmedicales.fr/author/Gloria%20Proni", "affiliation": { "@type": "Organization", "name": "John Jay College of Criminal Justice, New York, 524 West 59(th) Street, New York, NY 10019, USA. Electronic address: gproni@jjay.cuny.edu." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Decoding reappraisal and suppression from neural circuits: A combined supervised and unsupervised machine learning approach.", "datePublished": "2023-03-28", "url": "https://questionsmedicales.fr/article/36977965", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3758/s13415-023-01076-6" } }, { "@type": "ScholarlyArticle", "name": "Analysis of COVID-19 vaccine adverse event using language model and unsupervised machine learning.", "datePublished": "2023-02-21", "url": "https://questionsmedicales.fr/article/36802407", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0282119" } }, { "@type": "ScholarlyArticle", "name": "Driving behavior classification at signalized intersections using vehicle kinematics: Application of unsupervised machine learning.", "datePublished": "2022-07-25", "url": "https://questionsmedicales.fr/article/35877962", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/17457300.2022.2103573" } }, { "@type": "ScholarlyArticle", "name": "Early Detection of Cervical Cancer by Fluorescence Lifetime Imaging Microscopy Combined with Unsupervised Machine Learning.", "datePublished": "2022-09-29", "url": "https://questionsmedicales.fr/article/36232778", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms231911476" } }, { "@type": "ScholarlyArticle", "name": "Establishment of a new classification system for chronic inflammatory demyelinating polyneuropathy based on unsupervised machine learning.", "datePublished": "2022-08-27", "url": "https://questionsmedicales.fr/article/36054019", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/mus.27702" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Indoles", "item": "https://questionsmedicales.fr/mesh/D007211" }, { "@type": "ListItem", "position": 6, "name": "Indolequinones", "item": "https://questionsmedicales.fr/mesh/D045563" }, { "@type": "ListItem", "position": 7, "name": "Mitomycines", "item": "https://questionsmedicales.fr/mesh/D008937" }, { "@type": "ListItem", "position": 8, "name": "Mitomycine", "item": "https://questionsmedicales.fr/mesh/D016685" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Mitomycine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Mitomycine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Mitomycine", "description": "Comment la mitomycine est-elle administrée ?\nQuels tests sont nécessaires avant traitement ?\nLa mitomycine est-elle utilisée pour tous les cancers ?\nQuels marqueurs tumoraux sont surveillés ?\nY a-t-il des contre-indications au traitement ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Unsupervised+Machine+Learning&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Mitomycine", "description": "Quels sont les effets secondaires courants ?\nLa mitomycine cause-t-elle des douleurs ?\nQuels symptômes indiquent une réaction allergique ?\nPeut-elle affecter le système immunitaire ?\nQuels signes de toxicité doivent alerter ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Unsupervised+Machine+Learning&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Mitomycine", "description": "Comment minimiser les effets secondaires ?\nDes vaccinations sont-elles nécessaires ?\nComment éviter les infections pendant le traitement ?\nY a-t-il des recommandations alimentaires ?\nComment gérer le stress pendant le traitement ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Unsupervised+Machine+Learning&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Mitomycine", "description": "La mitomycine est-elle utilisée seule ?\nQuelle est la durée du traitement ?\nComment surveiller l'efficacité du traitement ?\nQuels soins de soutien sont recommandés ?\nY a-t-il des interactions médicamenteuses ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Unsupervised+Machine+Learning&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Mitomycine", "description": "Quelles sont les complications possibles ?\nLa mitomycine peut-elle causer des cancers secondaires ?\nComment gérer une toxicité sévère ?\nQuels tests pour surveiller les complications ?\nY a-t-il des effets à long terme ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Unsupervised+Machine+Learning&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Mitomycine", "description": "Qui est à risque d'effets secondaires ?\nLes antécédents de cancer augmentent-ils le risque ?\nLe tabagisme influence-t-il le traitement ?\nY a-t-il des facteurs génétiques à considérer ?\nL'âge influence-t-il la tolérance au traitement ?", "url": "https://questionsmedicales.fr/mesh/D016685?mesh_terms=Unsupervised+Machine+Learning&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment la mitomycine est-elle administrée ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La mitomycine est généralement administrée par injection intraveineuse ou intravésicale." } }, { "@type": "Question", "name": "Quels tests sont nécessaires avant traitement ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des examens d'imagerie sont souvent requis pour évaluer la santé du patient." } }, { "@type": "Question", "name": "La mitomycine est-elle utilisée pour tous les cancers ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Non, elle est principalement utilisée pour des cancers spécifiques comme le cancer de la vessie." } }, { "@type": "Question", "name": "Quels marqueurs tumoraux sont surveillés ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les marqueurs comme le CA 19-9 peuvent être surveillés selon le type de cancer traité." } }, { "@type": "Question", "name": "Y a-t-il des contre-indications au traitement ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents d'allergies ou de maladies rénales peuvent être des contre-indications." } }, { "@type": "Question", "name": "Quels sont les effets secondaires courants ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent nausées, vomissements, et fatigue." } }, { "@type": "Question", "name": "La mitomycine cause-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut provoquer des douleurs abdominales ou des douleurs au site d'injection." } }, { "@type": "Question", "name": "Quels symptômes indiquent une réaction allergique ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des démangeaisons, éruptions cutanées ou difficultés respiratoires peuvent indiquer une allergie." } }, { "@type": "Question", "name": "Peut-elle affecter le système immunitaire ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la mitomycine peut réduire les globules blancs, augmentant le risque d'infections." } }, { "@type": "Question", "name": "Quels signes de toxicité doivent alerter ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des saignements inhabituels ou des ecchymoses peuvent indiquer une toxicité." } }, { "@type": "Question", "name": "Comment minimiser les effets secondaires ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Une bonne hydratation et des médicaments antiémétiques peuvent aider à réduire les effets secondaires." } }, { "@type": "Question", "name": "Des vaccinations sont-elles nécessaires ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des vaccinations peuvent être recommandées pour prévenir les infections pendant le traitement." } }, { "@type": "Question", "name": "Comment éviter les infections pendant le traitement ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les foules et pratiquer une bonne hygiène peut aider à prévenir les infections." } }, { "@type": "Question", "name": "Y a-t-il des recommandations alimentaires ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée et riche en nutriments est recommandée pour soutenir le traitement." } }, { "@type": "Question", "name": "Comment gérer le stress pendant le traitement ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques de relaxation et le soutien psychologique peuvent aider à gérer le stress." } }, { "@type": "Question", "name": "La mitomycine est-elle utilisée seule ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut être utilisée seule ou en combinaison avec d'autres agents chimiothérapeutiques." } }, { "@type": "Question", "name": "Quelle est la durée du traitement ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La durée varie selon le type de cancer, mais elle est souvent administrée sur plusieurs cycles." } }, { "@type": "Question", "name": "Comment surveiller l'efficacité du traitement ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des examens d'imagerie et des tests sanguins réguliers sont utilisés pour évaluer l'efficacité." } }, { "@type": "Question", "name": "Quels soins de soutien sont recommandés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des soins de soutien comme la gestion de la douleur et des conseils nutritionnels sont recommandés." } }, { "@type": "Question", "name": "Y a-t-il des interactions médicamenteuses ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la mitomycine peut interagir avec d'autres médicaments, nécessitant une surveillance." } }, { "@type": "Question", "name": "Quelles sont les complications possibles ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent inclure des infections, des saignements et des problèmes rénaux." } }, { "@type": "Question", "name": "La mitomycine peut-elle causer des cancers secondaires ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'utilisation de mitomycine peut augmenter le risque de cancers secondaires à long terme." } }, { "@type": "Question", "name": "Comment gérer une toxicité sévère ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Une hospitalisation et un traitement symptomatique peuvent être nécessaires en cas de toxicité sévère." } }, { "@type": "Question", "name": "Quels tests pour surveiller les complications ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins réguliers et des examens d'imagerie sont nécessaires pour surveiller les complications." } }, { "@type": "Question", "name": "Y a-t-il des effets à long terme ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des effets à long terme peuvent inclure des problèmes pulmonaires ou rénaux, nécessitant un suivi." } }, { "@type": "Question", "name": "Qui est à risque d'effets secondaires ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées et celles avec des antécédents médicaux complexes sont plus à risque." } }, { "@type": "Question", "name": "Les antécédents de cancer augmentent-ils le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de cancer peuvent augmenter le risque d'effets secondaires lors du traitement." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il le traitement ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut affecter l'efficacité du traitement et augmenter les risques d'effets secondaires." } }, { "@type": "Question", "name": "Y a-t-il des facteurs génétiques à considérer ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certaines variations génétiques peuvent influencer la réponse au traitement par mitomycine." } }, { "@type": "Question", "name": "L'âge influence-t-il la tolérance au traitement ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les patients plus âgés peuvent avoir une tolérance réduite aux effets de la mitomycine." } } ] } ] }

Sources (10000 au total)

Analysis of COVID-19 vaccine adverse event using language model and unsupervised machine learning.

After the COVID-19 pandemic, the world has made efforts to recover from the chaotic situation. Vaccination is a way to help control infectious diseases, and many people have been vaccinated against CO... In this study, we examined people who experienced adverse events with the COVID-19 vaccine by gender, age, vaccine manufacturer, and dose of vaccinations by using the Vaccine Adverse Event Reporting S... We aim to contribute accurate information on the adverse events of the COVID-19 vaccine to relieve public anxiety due to unconfirmed statements about vaccines....

Driving behavior classification at signalized intersections using vehicle kinematics: Application of unsupervised machine learning.

Driving behavior is considered as a unique driving habit of each driver and has a significant impact on road safety. This study proposed a novel data-driven Machine Learning framework that can classif...

Establishment of a new classification system for chronic inflammatory demyelinating polyneuropathy based on unsupervised machine learning.

A model for predicting responsiveness to immunotherapy in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) has not been well established. We aimed to establish a new classifier f... The clinical, laboratory, and electrophysiological features of 172 treatment-naïve patients with CIDP between 2003 and 2019 were analyzed using an unsupervised hierarchical clustering. The identified ... Three clusters were identified: 1, n = 65; 2, n = 70; and 3, n = 37. Patients in Cluster 1 scored lower on the disability assessment score before treatment. More patients in Clusters 2 (90.0%) fulfill... The established hierarchical clustering with the tree-based model identified key features contributing to differences in disease severity and response to pulse steroid therapy. This classification sys...

Improvement of gram staining effect by ethanol pretreatment and quantization of staining image by unsupervised machine learning.

In this study, we propose an Ethanol Pretreatment Gram staining method that significantly enhances the color contrast of the stain, thereby improving the accuracy of judgement, and demonstrated the ef...

Association of comorbid-socioeconomic clusters with mortality in late onset epilepsy derived through unsupervised machine learning.

Late-onset epilepsy is a heterogenous entity associated with specific aetiologies and an elevated risk of premature mortality. Specific multimorbid-socioeconomic profiles and their unique prognostic t... We performed a retrospective observational cohort study linking primary and hospital-based UK electronic health records with vital statistics data (covering years 1998-2019) to identify all cases of i... From 1,032,129 people aged ≥65, we identified 1048 cases of late onset epilepsy who were matched to 10,259 controls. Median age at epilepsy diagnosis was 68 (interquartile range: 66-72) and 474 (45%) ... Late-onset epilepsy is an amalgam of unique phenotypic clusters that can be quantitatively defined. Late-onset epilepsy and cluster-specific comorbid profiles have complex effects on premature mortali...